A solid and healthy Association, ready for new and important challenges
A solid and healthy Association, ready for new and important challenges
Dear friends of Aicarm,
The Members' Assembly on 18 April represented an important step in the growth of our Association. The first annual report for 2023 has allowed us to define an organic and complete picture of the results achieved which fill us with great satisfaction. The numbers speak for themselves: the number of members, resident in 16 regions, is increasing, from 181 to 223, as are the volunteers, from 13 to 16, figures endowed with passion and skills capable of managing the necessary obligations with great professionalism administrative. From an economic point of view, the most significant data is the significant increase in liberal donations, an important indicator because it demonstrates our growing notoriety and reliability. The increase in revenue produced by the 5 per thousand is not negligible and the prospects for this year could be better.
These are significant data regarding the consolidation of the organizational and financial structure, the improvement of care for patients and their families as well as our information and communication activity. All this within the framework of an expansion of relations with institutional, scientific and economic entities of significant importance and international ones. In particular we will develop the active participation of AICARM along the lines indicated in the document "Cardiomyopathies matter”, presented in the Senate on March 19th. In particular, great attention will be paid to scientific research projects aimed at the well-being and health of patients, which will be announced and selected in the next few months of this year.
In terms of in-depth analysis of the issues that concern us, we continue our review of drugs with a profile by Dr. Alessandra Pistelli and with a comment by Dr. Francesca Torricelli, geneticist, regarding the results of the Survey promoted by AICARM on the availability of genetic testing at the main Italian medical genetics laboratories of the NHS for patients with cardiomyopathies published last March.
The President
Prof. Franco Cecchi
Procreation and physical activity in the foreground at the course for expert patients
The Milan course for Expert Patients in Hereditary Myocardial Diseases on March 23, 2024 was well attended. Those present created an interactive and collaborative environment. The exchange of information and experiences on crucial topics such as hereditary diseases and genetic counseling, arrhythmias and drug therapy is particularly useful and appreciated. Also in the foreground are issues related to contraception and procreation, aspects of vital importance that directly involve women, families and couples
Risk assessment of beta-blockers in pregnant women with cardiomyopathy
Therapy during pregnancy involves the use of various drugs including the beta-blocker family, used in the treatment of some cardiomyopathies, cardiac arrhythmias and arterial hypertension.
They are not responsible for an increase in the risk of birth defects, so in most cases pharmacological treatment during pregnancy is not only not contraindicated, but is absolutely recommended to maintain good clinical compensation of Cardiomyopathy, of fundamental importance for the regular progress of the pregnancy itself. In any case, management of these pregnancies by a multidisciplinary group that includes specialists in cardiology, obstetrics, obstetric ultrasound and echocardiography, perinatal toxicology, paediatrics is indicated.
Comment on the genetic survey (published in the March 2024 Newsletter)
We publish the comment of Dr. Francesca Torricelli, geneticist and former director of the Sod Diagnostica Genetica of the University Hospital of Careggi, relating to the results of the survey on the availability of the genetic test at the main Italian Medical Genetics laboratories of the NHS for patients with Cardiomyopathies published on Aicarm News of March 2024.
AICARM NEWS
AICARM NEWS
|
The AICARM APS budget for 2023 has been approved |
|
The ordinary meeting of the members of the AICARM APS association was held on 18 April last, in which the financial statements for the year 2023 were approved unanimously by the members present. During the meeting the President illustrated the numerous activities carried out in 2023 and those planned for 2024, then the budget project was presented which highlighted an Association with a solid and positive financial situation. All documentation relating to the assembly meeting can be consulted by visiting the following address: |
AICARM Onlus periodically publishes AICARM NEWS, the AICARM newsletter. You can receive the next releases directly in your e-mail box by filling out the form below. To consult the issues released, consult the page: AICARM NEWS, the AICARM newsletter.
Subscribe to AICARM NEWS
the AICARM APS Newsletter
Read our information on data processing Privacy Policy